Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

1. www.accessdata.fda.gov › drugsatfda_docs › labelReference ID: 4201583 - Food and Drug Administration

   www.accessdata.fda.gov › drugsatfda_docs › label

   POMALYST is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a...

2. labels.fda.govFDA Label Search

   labels.fda.gov

   • Αποθηκευμένο αντίγραφο

   Download All Labels Health information suppliers and others can download all of the electronic files companies have submitted from the National Library of Medicine’s Download Labels site....

3. www.pomalysthcp.com › access-resources › hcp-resourcesResources for healthcare professionals. - POMALYST®...

   www.pomalysthcp.com › access-resources › hcp-resources

   • Αποθηκευμένο αντίγραφο

   Review and download resources about POMALYST® (pomalidomide) for HCPs. See full prescribing info and BOXED WARNINGS on embryo fetal toxicity & thromboembolism.

4. www.accessdata.fda.gov › drugsatfda_docs › labelHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not...

   www.accessdata.fda.gov › drugsatfda_docs › label

   POMALYST is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe life-threatening birth defects (4, 5.1, 8.1). For females of reproductive potential: Exclude...

5. www.pomalysthcp.com › ksKaposi Sarcoma (KS) - POMALYST® (pomalidomide)

   www.pomalysthcp.com › ks

   • Αποθηκευμένο αντίγραφο

   Learn about POMALYST® (pomalidomide) for adult patients with Kaposi Sarcoma (KS) who are HIV-negative or have AIDS-related KS after HAART failure. See safety info BOXED WARNINGS including embryo-fetal tox, venous & arterial thromboembolism.

6. www.fda.gov › media › 144470Office of Clinical Pharmacology Integrated Review - U.S. Food and...

   www.fda.gov › media › 144470

   Pomalidomide (Pomalyst®) has been approved for two indications, multiple myeloma (MM) and Kaposi sarcoma (KS). The approved dosage of pomalidomide is 4 mg/day for adult MM patients and 5 mg/day...

7. www.bms.com › assets › bmsPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr...

   www.bms.com › assets › bms

   25 Ιαν 2024 · POMALYST® (pomalidomide) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. • Potential for human birth defects, stillbirths, and spontaneous abortions (see